semaglutide vs placebo in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Key Facts GPs Should Know

W., Zhang, D., & Shulman, G

The EMA committee will also investigate whether semaglutide can be proven to increase the risk of reduced blood flow to the optic nerve

This helps individuals eat less and feel satisfied with smaller portions, which supports weight loss

BP was supported by a consolidator investigator grant from Karolinska Institutet

Despite this difference, oral options provide convenience for patients who prefer avoiding needles and can integrate medication into a daily pill routine

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease